Quick Answer
LianBio reported Net Income of -$110.29 million for fiscal year 2022.
LianBio — Key Financials by Year
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Net Income | -$110.29M +43.8% |
-$196.30M -40.6% |
-$139.60M | — |
| Diluted EPS | -$1.02 +82.1% |
-$5.71 +50.7% |
-$11.58 | — |
| Total Assets | $319.96M -25.0% |
$426.34M +52.7% |
$279.29M | — |
| Cash and Equivalents | $79.22M -65.3% |
$228.18M -10.3% |
$254.35M | — |
| Stockholders Equity | $259.87M -26.5% |
$353.56M +366.2% |
-$132.84M -796.6% |
-$14.82M |
| R&D Expense | $59.76M -62.3% |
$158.69M +31.3% |
$120.89M | — |
| Operating Income | -$125.35M +35.9% |
-$195.57M -45.0% |
-$134.87M | — |
| Shares Outstanding | 107.04M -0.2% |
107.28M +423.9% |
20.48M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2023 | -$24.04M | -9.8% | -11.2% |
| Diluted EPS | September 30, 2023 | -$0.22 | -10.0% | -10.0% |
| Total Assets | September 30, 2023 | $262.90M | -25.3% | -5.7% |
| Cash and Equivalents | September 30, 2023 | $103.46M | +31.2% | -0.6% |
| Stockholders Equity | September 30, 2023 | $202.34M | -25.8% | -8.7% |
| R&D Expense | September 30, 2023 | $9.02M | +9.2% | -4.6% |
| Operating Income | September 30, 2023 | -$26.30M | -7.1% | -5.0% |
| Shares Outstanding | September 30, 2023 | 107.17M | -1.1% | +0.0% |
- LianBio reported Net Income of -$110.29 million for fiscal year 2022.
- LianBio showed an increase of +43.8% in Net Income compared to the prior fiscal year.
- LianBio reported Diluted EPS of $1.02 per share (loss) for fiscal year 2022.
- LianBio showed an increase of +82.1% in Diluted EPS compared to the prior fiscal year.
- LianBio reported Total Assets of $319.96 million for fiscal year 2022.
- LianBio showed a decrease of -25.0% in Total Assets compared to the prior fiscal year.
- LianBio reported Cash and Equivalents of $79.22 million for fiscal year 2022.
- LianBio showed a decrease of -65.3% in Cash and Equivalents compared to the prior fiscal year.
- LianBio reported Stockholders Equity of $259.87 million for fiscal year 2022.
- LianBio showed a decrease of -26.5% in Stockholders Equity compared to the prior fiscal year.
- LianBio reported R&D Expense of $59.76 million for fiscal year 2022.
- LianBio showed a decrease of -62.3% in R&D Expense compared to the prior fiscal year.
- LianBio reported Operating Income of -$125.35 million for fiscal year 2022.
- LianBio showed an increase of +35.9% in Operating Income compared to the prior fiscal year.
- LianBio reported Shares Outstanding of 107.04 million shares for fiscal year 2022.
- LianBio showed a decrease of -0.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: